Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 08:00 ET | Source: Foresight Diagnostics, Inc.

Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference

BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease...
January 10, 2025 08:03 ET | Source: Foresight Diagnostics, Inc.

NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating...
January 08, 2025 08:30 ET | Source: Foresight Diagnostics, Inc.

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the use of Foresight CLARITY™ for patient enrollment in the ALPHA3 clinical...
September 10, 2024 09:00 ET | Source: Foresight Diagnostics, Inc.

Foresight Diagnostics to Present New Data on Foresight CLARITY™ MRD in Early-Stage Breast Cancer at ESMO Congress 2024

BOULDER, Colo., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection, today announced an upcoming presentation...
July 30, 2024 07:00 ET | Source: Foresight Diagnostics, Inc.

Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform

BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease...